Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SNDX-5613 is a potent and specific inhibitor of Menin-MLL(Ki of 0.149 nM and a cell based IC50 of 10-20 nM). SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 67.00 | |
2 mg | In stock | $ 98.00 | |
5 mg | In stock | $ 163.00 | |
10 mg | In stock | $ 288.00 | |
25 mg | In stock | $ 571.00 | |
50 mg | In stock | $ 819.00 | |
100 mg | In stock | $ 1,130.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 229.00 |
Description | SNDX-5613 is a potent and specific inhibitor of Menin-MLL(Ki of 0.149 nM and a cell based IC50 of 10-20 nM). SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias. |
Targets&IC50 | Menin-MLL:10-20 nM |
In vivo | SNDX-5613 treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts.SNDX-5613 shows in vivo plasma( IC50 : 53 nM) . |
Molecular Weight | 630.82 |
Formula | C32H47FN6O4S |
CAS No. | 2169919-21-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (95.11 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SNDX-5613 2169919-21-3 Chromatin/Epigenetic Epigenetic Reader Domain Histone Methyltransferase acute SNDX 5613 SNDX5613 Leukemia inhibit lymphoblastic Inhibitor AML Menin ALL MLL myeloid inhibitor